^
    CD20 positive
    Follicular Lymphoma
    obinutuzumab + INCB50465
    Sensitive: C3 – Early Trials
    EHA 2022 - 4 days - (New C3)
    No biomarker
    Follicular Lymphoma
    tisagenlecleucel-T
    Sensitive: A1 - Approval
    Novartis Press Release - 1 week - (New A1)
    No biomarker
    Follicular Lymphoma
    axicabtagene ciloleucel
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    rituximab + lenalidomide
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    Truxima (rituximab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    Rixathon (rituximab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    Ruxience (rituximab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    obinutuzumab
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    rituximab
    Sensitive: A1 - Approval
    CD20 positive
    Follicular Lymphoma
    rituximab + ibritumomab tiuxetan
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    ibritumomab tiuxetan
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    idelalisib
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    duvelisib
    Sensitive: A1 - Approval
    EZH2 wild-type
    Follicular Lymphoma
    tazemetostat
    Sensitive: A1 - Approval
    EZH2 mutation
    Follicular Lymphoma
    tazemetostat
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    copanlisib
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    umbralisib
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    lisocabtagene maraleucel
    Sensitive: A1 - Approval
    CD20 positive
    Follicular Lymphoma
    Ruxience (rituximab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    rituximab / hyaluronidase
    Sensitive: A1 - Approval
    No biomarker
    Follicular Lymphoma
    R-CHOP
    Sensitive: A2 - Guideline
    No biomarker
    Follicular Lymphoma
    R-CVP
    Sensitive: A2 - Guideline
    No biomarker
    Follicular Lymphoma
    rituximab + obinutuzumab
    Sensitive: A2 - Guideline
    No biomarker
    Follicular Lymphoma
    lenalidomide
    Sensitive: A2 - Guideline
    No biomarker
    Follicular Lymphoma
    chlorambucil
    Sensitive: A2 - Guideline
    No biomarker
    Follicular Lymphoma
    lenalidomide + obinutuzumab
    Sensitive: A2 - Guideline
    No biomarker
    Follicular Lymphoma
    cyclophosphamide
    Sensitive: A2 - Guideline
    No biomarker
    Follicular Lymphoma
    G-CHOP
    Sensitive: A2 - Guideline
    No biomarker
    Follicular Lymphoma
    CG-781
    Sensitive: B - Late Trials
    BCL2 elevation + IGH elevation
    Follicular Lymphoma
    rituximab
    Resistant: B - Late Trials
    No biomarker
    Follicular Lymphoma
    INCB50465
    Sensitive: B - Late Trials
    CD20 positive
    Follicular Lymphoma
    Truxima (rituximab biosimilar)
    Sensitive: C1 - Off-label
    CD20 positive
    Follicular Lymphoma
    GEN3013
    Sensitive: C2 – Inclusion Criteria
    BCL2 mutation
    Follicular Lymphoma
    nivolumab + ibrutinib
    Sensitive: C3 – Early Trials
    CXCL11 elevation
    Follicular Lymphoma
    duvelisib
    Resistant: C3 – Early Trials
    IL2RA elevation
    Follicular Lymphoma
    duvelisib
    Resistant: C3 – Early Trials
    Chr del(6q)(q15)
    Follicular Lymphoma
    duvelisib
    Sensitive: C3 – Early Trials
    EZH2 mutation
    Follicular Lymphoma
    rituximab
    Resistant: C3 – Early Trials
    KMT2D mutation
    Follicular Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    ARID1B mutation
    Follicular Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    BCL7A mutation
    Follicular Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    TNFAIP3 mutation
    Follicular Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    GNA13 mutation
    Follicular Lymphoma
    R-CHOP
    Sensitive: C3 – Early Trials
    CTSS Y132D
    Follicular Lymphoma
    R-CHOP
    Sensitive: C3 – Early Trials
    GNA12 mutation
    Follicular Lymphoma
    R-CHOP
    Sensitive: C3 – Early Trials
    PLCG2 mutation
    Follicular Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    IL2-L
    Follicular Lymphoma
    rituximab
    Sensitive: C3 – Early Trials
    FCGR2A mutation
    Follicular Lymphoma
    rituximab + lenalidomide
    Sensitive: C3 – Early Trials
    TBX21 overexpression
    Follicular Lymphoma
    nivolumab + ibrutinib
    Sensitive: C3 – Early Trials
    LDH elevation
    Follicular Lymphoma
    ViPOR
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL6 rearrangement
    Follicular Lymphoma
    EPOCH-R
    Resistant: C3 – Early Trials
    MYC rearrangement
    Follicular Lymphoma
    EPOCH-R
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Follicular Lymphoma
    EPOCH-R
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Follicular Lymphoma
    R-DHAP
    Sensitive: C3 – Early Trials
    IL2RA-L
    Follicular Lymphoma
    nivolumab
    Sensitive: C3 – Early Trials
    CD20 positive
    Follicular Lymphoma
    MB-106
    Sensitive: C3 – Early Trials
    HAVCR2 expression
    Follicular Lymphoma
    venetoclax + atezolizumab + obinutuzumab
    Sensitive: C3 – Early Trials
    CCL19 overexpression
    Follicular Lymphoma
    rituximab
    Sensitive: C3 – Early Trials
    RGL1 overexpression
    Follicular Lymphoma
    rituximab
    Sensitive: C3 – Early Trials
    CCL19-H
    Follicular Lymphoma
    rituximab
    Sensitive: C3 – Early Trials
    CD20 positive
    Follicular Lymphoma
    rituximab + lenalidomide + GEN3013
    Sensitive: C3 – Early Trials
    TMB-H
    Follicular Lymphoma
    venetoclax + obinutuzumab
    Sensitive: C3 – Early Trials
    CD20 positive
    Follicular Lymphoma
    rituximab + CC-122
    Sensitive: C3 – Early Trials
    BCL2 F104I
    Follicular Lymphoma
    venetoclax
    Resistant: C4 – Case Studies
    PD-L1 overexpression
    Follicular Lymphoma
    PD-L1 inhibitor
    Sensitive: C4 – Case Studies
    PD-L1 overexpression
    Follicular Lymphoma
    R-GemOx
    Resistant: C4 – Case Studies
    PD-L1 overexpression
    Follicular Lymphoma
    R-CHOP
    Resistant: C4 – Case Studies
    CREBBP mutation
    Follicular Lymphoma
    YF2
    Sensitive: D – Preclinical
    TP53 mutation
    Follicular Lymphoma
    YF2
    Sensitive: D – Preclinical
    EZH2 mutation
    Follicular Lymphoma
    CPI-169
    Sensitive: D – Preclinical
    TBX21 expression
    Follicular Lymphoma
    nivolumab + ibrutinib
    Sensitive: D – Preclinical